TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00539500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin by vein over 24 hours for 4 days, dosing as determined at day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 300 mg/m\^2 by vein over 24 hours for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 Intravenous Bolus for 3 Days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem Cell Infusion (approximately 5x10\^8 TNC cells/kg CD133+ selected) on Day 0.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClinicMACS
Description: Device used to process the blood and separate the CD 133+ cells needed for transplantation
Study: NCT03716193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Patients will be given oxygen via a facemask during the measurement session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Patients will be given oxygen via a facemask during the measurement session
Study: NCT04100018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT00748605

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-2367 Placebo
Description: Four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet for 6 weeks) and RCD (reduced calorie diet for 54 weeks) for a total of 60 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-2367 Placebo
Description: Four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet for 6 weeks) and RCD (reduced calorie diet for 54 weeks) for a total of 60 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-2367 1600 mg q.d. 54 Weeks
Description: Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on RCD for a total of 54 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-2367 1600 mg q.d. 60 weeks
Description: Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on both LCD and RCD for a total of 60 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LCD (low calorie diet)
Description: A low calorie diet was utilized during the first 6 weeks of the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCD (low calorie diet)
Description: A low calorie diet was utilized during the first 6 weeks of the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCD (low calorie diet)
Description: A low calorie diet was utilized during the first 6 weeks of the study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RCD (reduced calorie diet)
Description: A reduced calorie diet was used during the last 54 weeks for the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RCD (reduced calorie diet)
Description: A reduced calorie diet was used during the last 54 weeks for the study
Study: NCT03477565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape lymphatic drainage technique application
Description: Kinesio Tex Tape strips are applied following Dr.Kase draining techinique. The choice of tape's length and strips' number is based on the area of breast edema and/or presence of seroma, which must be completely covered. The patch is cut into fan strips. The major base is positioned near the functioning lymph node stations closest to the edema and/or seroma area. The bases and the tails of the fan must be applied with zero tension, while for the central part is reached 15-25% of tension. The first application takes place on the 1st post-operative day, while the second is performed on the 7th post-operative day. In case the tape is detached from one application to another, it is necessary that the patient resume in the clinic for a new application to ensure continuity of the therapeutic effect; otherwise the patient is eliminated from the study. The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and counselin.
Study: NCT03013491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-072
Study: NCT00748605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RCD (reduced calorie diet)
Description: A reduced calorie diet was used during the last 54 weeks for the study
Study: NCT03828526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fidelity Simulation
Description: Teaching strategy based on high fidelity simulation, which simulates the reality of health care to promote meaningful learning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional teaching strategy
Description: Classroom-based strategy
Study: NCT03708315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: Dexmedetomidine Hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study: NCT00751985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalised normative feedback (PNF)
Description: The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The brief personalised normative feedback will comprise the result of the participant's amount of alcohol consumption, previously given in an online questionnaire.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. The feedback is also comparing their drinking, in graphical format, to the average drinking in the municipality concerned. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help material
Description: The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The intervention comprises of on-line self-help material informing about the participant's response from an online questionnaire shows that the participant's alcohol consumption exceeds the recommended limits.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The participant is being informed about their allocation to the control group.
Study: NCT00980798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone HCl
Description: 4 to 32 mg taken orally once daily for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet once daily for 16 weeks
Study: NCT00631917

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Aliskiren
Description: Placebo tablets to match aliskiren.
Study: NCT01208467

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02651831

Intervention type: OTHER
Intervention: Focus groups and individual interviews
Description: Focus groups conducted to explore general experiences, insights and concerns of those receiving ICM therapies. Individual semi-structured interviews to provide in-depth data on the themes identified in the focus groups.

Intervention type: OTHER
Intervention: Questionnaire
Description: Health related quality of life questionnaire (FACT-ICM) to be completed by patients

Intervention type: OTHER
Intervention: Questionnaire
Description: Health related quality of life questionnaire (FACT-ICM) to be completed by patients

Intervention type: OTHER
Intervention: Questionnaire
Description: Health related quality of life questionnaire (FACT-ICM) to be completed by patients

Intervention type: OTHER
Intervention: Questionnaire
Description: Health related quality of life questionnaire (FACT-ICM) to be completed by patients
Study: NCT03334591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg with Docetaxel 60mg/m2
Study: NCT00145535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOLX Titanium Sapphire Laser (TiSaLT)
Description: Spot laser treatment, \~50 spots over 180°

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Laser Trabeculoplasty (ALT)
Description: Spot laser treatment, \~50 spots over 180°
Study: NCT03334591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Apatinib 500mg with Docetaxel 60mg/m2
Study: NCT01254292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD (LCS, BAY86-5028)
Description: LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin (EE30/DRSP, BAY86-5131)
Description: Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
Study: NCT01103336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pretreatment with intravenous nicorandil vs. placebo before coronary angiography
Description: * Nicorandil group: Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography~* Control group: Pretreatment with intravenous 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pretreatment with intravenous nicorandil vs. placebo before coronary angiography
Description: * Nicorandil group: Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography~* Control group: Pretreatment with intravenous 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography
Study: NCT05836181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing
Description: Effects of Eye Movement Desensitization and Reprocessing on Anxiety, Depression, Quality of Life, Blood Pressure and Heart Rate Variability in Patients with Hypertension.
Study: NCT04432259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg bid for 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo
Study: NCT01479127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-SLV187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Levodopa/Carbidopa
Description: Tablet; contains 100 mg levodopa and 10 mg carbidopa

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion Pump: CADD-Legacy® 1400 Pump
Description: General infusion pump, manufactured by Smiths Medical (US)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NJ-Tube: Silicon ED Tube
Description: Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptor: Hakko Adaptor
Description: Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)
Study: NCT00003831

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT03868761

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sonoma Rises
Description: All participants will receive the intervention, Sonoma Rises, a mobile app designed by psychologists at the National Center for PTSD for wildfire survivors to facilitate recovery from disaster. Users can access evidence-informed tools to help cope with stress, heal from loss, prioritize self-care, connect with others, manage anger, and track their mood using validated assessments. There are also tools designed just for teens and users are linked to psychoeducation on disaster and health and other mental health resources and services.
Study: NCT04225962

Intervention type: OTHER
Intervention: Intimate quality of life questionnaire
Description: Preparation of an intimate quality of life questionnaire
Study: NCT03495037

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real World Strategy Training
Description: The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial Education
Description: The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
Study: NCT01986946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epidural Catheter - Dilaudid
Description: Placement of an epidural catheter to administer local anesthetic and opioid (dilaudid) to the epidural space will be studied as compared to use of intravenous opioid (dilaudid) for pain control following lumbar spine fusion surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilaudid
Description: Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
Study: NCT02081287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP6
Description: IP6 2,000 -3,000 mg per day given orally in two doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Dose up to 200 mg per day over 10 weeks
Study: NCT04374071

Intervention type: DRUG
Intervention: Methylprednisolone
Description: IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days
Study: NCT00061347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fiducial marker placement
Description: Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
Study: NCT02527993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucobay (acarbose)
Description: Se arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Januvia (sitagliptin)
Description: Se arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil HEXAL (verapamil)
Description: Se arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza (liraglutide)
Description: Se arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Signifor (pasireotide)
Description: Se arm description

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Description: Continuous glucose monitoring will be performed during 6 days of the treatment period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Description: Continuous glucose monitoring will be performed during 6 days of the treatment period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Description: Continuous glucose monitoring will be performed during 6 days of the treatment period.
Study: NCT03013491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-072
Study: NCT00006228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study: NCT03013491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Study: NCT00006228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02527993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Description: Continuous glucose monitoring will be performed during 6 days of the treatment period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal tolerance test (MTT)
Description: A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal tolerance test (MTT)
Description: A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal tolerance test (MTT)
Description: A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal tolerance test (MTT)
Description: A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal tolerance test (MTT)
Description: A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
Study: NCT04674644

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The psychosocial effects of COVID-19 pandemic on dental professionals
Description: Analysing the psychosocial effects of COVID-19 pandemic on dental professionals using the Turkish version of the Fear of COVID-19 and Coronavirus Anxiety Scales
Study: NCT04067882

Intervention type: OTHER
Intervention: Genetic signature
Description: The RNA will be extracted from the tumor sample with a special kit and a q-PCR will be performed. In order to quantify the genetic expression, the comparative method called Cycle threshold or Crossing point will be used.
Study: NCT01881919

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Address: Nature's Best, Century Place, Tunbridge Wells, Kent, TN2 3BE Phone:+44(0)1892 552030 Email:info@naturesbest.co.uk

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Address: Fagron GmbH\&Co. KG, 22885 Barsbuttel, Germany Phone: +49(0)4067067680
Study: NCT02140554

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: lovo-cel
Description: lovo-cel is administered by IV infusion following myeloablative conditioning with busulfan.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: lovo-cel
Description: lovo-cel is administered by IV infusion following myeloablative conditioning with busulfan.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: lovo-cel
Description: lovo-cel is administered by IV infusion following myeloablative conditioning with busulfan.
Study: NCT01219855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 CTAP101 Capsules- 60µg
Description: 60µg of CTAP101 capsules given once daily for 42 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 CTAP101 Capsules - 90µg
Description: 90µg of CTAP101 capsules given once daily for 42 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 1 Matching Sugar Capsule
Description: Placebo capsules given once daily for 42 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 CTAP101 Capsules - 30µg
Description: 30µg of CTAP101 capsules given once daily for 42 days.
Study: NCT03013491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Study: NCT04316689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S-488210
Description: S-488210 is a freeze-dried injectable formulation containing the following three peptides, S-488201 (a URLC10-derived peptide), S-488202 (a CDCA1-derived peptide) and S-488203 (a KOC1-derived peptide).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S-488211
Description: S-488211 is a freeze-dried injectable formulation containing the following two peptides, S-488204 (a DEPDC1-derived peptide) and S-488205 (an MPHOSPH1-derived peptide).
Study: NCT01035606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training in goal-directed attention regulation
Description: training in goal-directed attention regulation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: brain health education
Description: brain health education workshops

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-assisted training in goal-directed attention regulation
Description: computer-assisted training in goal-directed attention regulation, with trainer guidance and cognitive games to practice skills
Study: NCT03536312

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Thoracic Aortic Surgery
Description: Thoracic aortic surgery to treat thoracic aortic aneurysm
Study: NCT01427569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IZN-6D4 Gel
Description: Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo hydrogel
Description: Standard wound therapy plus twice weekly topical application of color-matched placebo hydrogel